

BIOCRYST PHARMACEUTICALS INC

Form 8-K

January 10, 2008

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 10, 2008, BioCryst Pharmaceuticals, Inc. (the Company) announced it had hired Thomas J. Simon as a consultant and interim Chief Medical Officer. The Company has undertaken a search to find a permanent successor to Dr. Simon.

As a result of this change, Dr. W. James Alexander will assume the role of Vice President Clinical Development.

Item 9.01. Financial Statements and Exhibits:

| Exhibit No. | Description |
|--------------------|--|
| 99.1 | Press release dated January 10, 2008 entitled BioCryst Strengthens Its Expertise in Clinical Development by adding Thomas J. Simon, M.D. as Interim Chief Medical Officer to Meet Growing Product Development and Commercial Opportunities |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 10, 2008

BioCryst Pharmaceuticals, Inc.

By: /s/ Michael A. Darwin

Michael A. Darwin
Vice President Finance

EXHIBIT INDEX

| Exhibit No. | Description |
|--------------------|--|
| 99.1 | Press release dated January 10, 2008 entitled BioCryst Strengthens Its Expertise in Clinical Development by adding Thomas J. Simon, M.D. as Interim Chief Medical Officer to Meet Growing Product Development and Commercial Opportunities |